Defining the first bona fide cell model for SMARCA4-deficient, undifferentiated tumor

Area of Science:

• Oncology
• Cancer Biology
• Genetics

Background:

• The World Health Organization frequently updates tumor classification based on advancing cancer biology.
• A novel lung tumor subtype, SMARCA4-deficient, undifferentiated tumor (SMARCA4-dUT), was included in the 2021 classification.
• Currently, no established cell model exists for SMARCA4-dUT, impeding research and clinical study.

Purpose of the Study:

• To identify a bona fide cell model for the experimental study of SMARCA4-deficient, undifferentiated tumors (SMARCA4-dUT).
• To re-evaluate existing lung adenocarcinoma (LUAD) cell lines for potential reclassification as SMARCA4-dUT.

Main Methods:

• Comparative analysis of gene expression profiles for 36 LUAD and 38 rhabdoid cell lines.
• Integration of SWI/SNF complex mutation and expression data with SMARCA4-dUT marker analysis (SOX2, SALL4, CD34) via RT-qPCR and western blotting.
• Engraftment of candidate cell lines into immunocompromised mice to assess tumor morphology and compare with LUAD models.

Main Results:

• The NCI-H522 cell line, previously classified as LUAD, showed expression profiles closer to rhabdoid tumors.
• NCI-H522 exhibits key SMARCA4-dUT features: SMARCA4 mutation, SMARCA2 downregulation, and high SOX2/SALL4 expression.
• Engrafted NCI-H522 tumors displayed undifferentiated morphology, distinct from differentiated LUAD tumors (e.g., A549).

Conclusions:

• The NCI-H522 cell line is proposed as the first bona fide model for SMARCA4-deficient, undifferentiated tumors (SMARCA4-dUT).
• This model will facilitate further research into the biology and potential therapeutic strategies for SMARCA4-dUT.
• The findings highlight the importance of re-evaluating existing cell lines in light of updated cancer classifications.